HTA Council Recommendation (as of 13 April 2023) The HTA Council does not recommend government financing of cerebrolysin 215.2mg/mL , 10 mL ampule for IV infusion, in combination with rehabilitation, for the treatment of adults post-ischemic stroke, thus its non-inclusion in the Philippine National Formulary. (See below for more details) Relevant Information Evidence and Relevant continue reading : Cerebrolysin [215.2 mg/mL, 10mL ampule for IV infusion] for the treatment of post-ischemic stroke
Aflibercept [2mg intravitreal injection] for first-line treatment of Wet Age-related Macular Degeneration
Assessment Status Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Abiraterone acetate [250 mg tablet] in combination with prednisone as first-line or second-line treatment of metastatic castration-resistant prostate cancer (mCRPC)
HTA Council Recommendation (as of 23 November 2022) The HTA Council recommends the government financing of abiraterone acetate (250mg tablet) in combination with prednisone (PD) as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC) through its inclusion in the Philippine National Formulary. Relevant Information Evidence and Relevant Documents Assessment History Back to continue reading : Abiraterone acetate [250 mg tablet] in combination with prednisone as first-line or second-line treatment of metastatic castration-resistant prostate cancer (mCRPC)